Vivacity-MG3 study comparing nipocalimab versus placebo treatment in patients with generalized myasthenia gravis: A Plain Language Summary of Publication

Plain language summaryWhat is this summary about?Generalized myasthenia gravis (gMG) is a long-term autoimmune disease where the immune system attacks the nerve-muscle junction causing muscle weakness. This summary describes results from Vivacity-MG3, a 24-week Phase-3 randomized controlled trial, that investigated whether nipocalimab is safe and improves symptoms in patients with gMG who did not get sufficient symptom relief with standard-of-care treatments. Participants could have autoantibodies for acetylcholine receptor [AChR], muscle-specific tyrosine kinase receptor-related protein [MuSK], or low-density lipoprotein receptor-related protein-4 [LRP4].What were the results?The study included 196 patients, who were receiving standard-of-care treatments for gMG. In addition to standard-of-care treatments, 98 patients received nipocalimab, while the remaining 98 received placebo. Over 24-weeks, nipocalimab-treated patients showed greater improvements in gMG symptoms compared to placebo. The most common side effects were COVID-19-related side effects, headache, muscle spasms, myasthenia gravis worsening, and peripheral edema.What do the results mean?In patients with gMG who are positive for antibodies to AChR, MuSK, or LRP4, nipocalimab added to standard-of-care treatments was an effective treatment with a tolerable safety profile after 24-weeks of treatment. The efficacy and safety of nipocalimab when used for longer than 24-weeks is being evaluated in an ongoing open-label extension of this study.How to say…Myasthenia gravis: mai-uhs-thee-nee-uh gra-vuhsNipocalimab: Ni-po-KA-li-mabPlacebo: Pluh-SEE-bohAutoimmune: A health condition that happens when the body’s immune system attacks the human body instead of defending it.Randomized placebo-controlled trial: A type of study where participants are divided by chance into different groups where one group receives the active treatment being tested and the other group receives placebo.Standard-of-care treatments in gMG: For this study, it included acetylcholinesterase inhibitors (eg. pyridostigmine), corticosteroids, and non-steroid immunosuppressants (eg. azathioprine).Autoantibodies: Are kind of antibodies that mistakenly attack the body’s own healthy cells and tissues. Autoantibodies are harmful and may lead to development of an autoimmune disease such as gMG.Placebo: A treatment that looks just like the real study medicine but does not contain any active medicine. It is used in research to help show whether the real study medicine works better than no treatment.Myasthenia gravis worsening: Some patients experience increase in muscle weakness, even while they are receiving treatment, due to the fluctuating nature of the disease and individual differences in treatment response.Peripheral edema: Swelling in areas of the body, most commonly the feet, ankles, or legs or hands. It happens when excess fluid builds up in the tissues and may cause the affected area to look puffy or feel tight.Safety profile: A summary of how safe a treatment is, based on the types and frequencies of side effects seen in people who received it during the study.Efficacy: The ability to produce the desired or intended results, for example, with a medication.Open-label extension: A follow-up to a clinical trial where both the researchers and participants know that everyone is receiving the active treatment. This allows researchers to gather long-term safety and effectiveness data on the active treatment being tested.This is an abstract of the Plain Language Summary of Publication article.View the full Plain Language Summary PDF of this article to read the full-textLink to original article hereTrial registration: ClinicalTrials.gov identifier: NCT04951622.